Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by S. A. Jacobs
Full-Dose 90Y Ibritumomab Tiuxetan Therapy Is Safe in Patients With Prior Myeloablative Chemotherapy
Clinical Cancer Research
Cancer Research
Oncology
Domain Structure and Dynamics in the Helical Filaments Formed by RecA and Rad51 on DNA
Proceedings of the National Academy of Sciences of the United States of America
Multidisciplinary
Related publications
MIRD Dose Estimate Report No. 20: Radiation Absorbed-Dose Estimates for 111In- And 90y-Ibritumomab Tiuxetan
Journal of Nuclear Medicine
Medicine
Nuclear Medicine
Radiology
Imaging
Radioimmunotherapy With 90y-Ibritumomab Tiuxetan Is a Safe and Efficient Treatment for Patients With B-Cell Lymphoma Relapsed After Auto-Sct: An Analysis of the International RIT-Network
Bone Marrow Transplantation
Transplantation
Hematology
A New Pharmacokinetic Model for 90y-Ibritumomab Tiuxetan Based on 3-Dimensional Dosimetry
Scientific Reports
Multidisciplinary
Positron Emission Tomography/Computed Tomography Before Treatment as a Predictor of 90y-Ibritumomab Tiuxetan Response
Kitakanto Medical Journal
Medicine
Myeloablative Timed Sequential Busulfan Is Safe in Patients With Relapsed or High-Risk Multiple Myeloma
Biology of Blood and Marrow Transplantation
Transplantation
Hematology
Radioimmunotherapy for B-Cell Lymphoma: Y90 Ibritumomab Tiuxetan and I131 Tositumomab
Oncogene
Cancer Research
Genetics
Molecular Biology
Hepatic Imaging Response to 90y-Microsphere Therapy Administered for Tumor Progression During Systemic Chemotherapy in Patients With Colorectal Liver Metastases.
Journal of Clinical Oncology
Cancer Research
Medicine
Oncology
Myeloablative Haploidentical Transplantation Is Superior to Chemotherapy for Patients With Intermediate-Risk Acute Myelogenous Leukemia in First Complete Remission
Clinical Cancer Research
Cancer Research
Oncology
Escalating-Dose HLA-mismatched DLI Is Safe for the Treatment of Leukaemia Relapse Following Alemtuzumab-Based Myeloablative Allo-SCT
Bone Marrow Transplantation
Transplantation
Hematology
